Arphamid Therapeutics is developing a portfolio of small-molecule drugs for the treatment of various endocrine disorders, such as obesity, diabetes, substance abuse and depression. The start-up has a platform of RF-amide receptor modulators, which are endogenous receptors for specific neuroendocrine peptides involved in a number of highly important physiological functions in humans. Arphamid’s most advanced programme focuses on GPR103 receptor antagonists, and its lead drug candidate is ready for pre-IND studies with a view to entering clinical development.